Natalia Andreevna Batmanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Natalia Andreevna Batmanova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Timur Teimurazovich Valiev
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
5 shared publications - Meri A. Shervashidze
LA Durnov Research Institute of Pediatric Oncology and Hematology, NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
4 shared publications - Svetlana R. Varfolomeeva
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
3 shared publications - Kirill I. Kirgizov
Research Institute of Pediatric Oncology and Hematology, FSBI “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of Russia, Kashirskoye sh. 23, Moscow 115522, Russia
2 shared publications - Daria S. Smirnova
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
1 shared publication - G. A. Aleskerova
National Center for Oncology, Ministry of Health of the Republic of Azerbaijan
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 375-383
Treatment Outcomes in Children with Relapsed Acute Lymphoblastic Leukemia Using ALL-REZ BFM 2002 Protocol: Data from a Single-Center Trial
BACKGROUND. Despite considerable therapy success in newly diagnosed pediatric acute lymphoblastic leukemia (ALL), treatment of relapses remains challenging and requires a personalized approach. In the Russian Federation, the treatment of relapsed ALL is based on ALL-REZ BFM 2002, the protocol suggesting a risk-adapted strategy with assessing eligibility for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in high-risk patients. Global and national experience with implementation of this program demonstrated a therapeutic plateau, which indicates the need for modernizing the standard chemotherapy regimens and introducing novel targeted and immunological approaches. AIM. To assess the long-term outcomes of treating children with the first ALL relapse using ALL-REZ BFM 2002 at a single medical center. MATERIALS & METHODS. This study enrolled 73 patients with the confirmed diagnosis of the first ALL relapse who received a complete course of therapy according to ALL-REZ BFM 2002 at the Hematologic Malignancy Units No. 1 and No. 2 at the Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Cancer Research Center, from 2018 to 2024. The median age was 9.3 years (range 3–17 years), most of them were boys (71 %). The data analysis was conducted as of February 1, 2026. RESULTS. The analysis of the total cohort showed the 5-year overall survival of 54.6 % and event-free survival of 48.7 % (in the S1 and S2 risk subgroups 100 % and 52.2 %, respectively). Allo-HSCT improved the 5-year disease-free survival (DFS) up to 72.5 %. The administration of targeted immunotherapy with blinatumomab or inotuzumab ozogamicin as bridge therapy prior to allo-HSCT in minimal residual disease (MRD)-positive patients resulted in further improvement of this rate up to 83.6 %. CONCLUSION. The risk-adapted ALL-REZ BFM 2002 protocol shows efficacy in patients with the first ALL relapse. Introducing blinatumomab/inotuzumab ozogamicin to achieve MRD-negative remissions prior to allo-HSCT improves DFS rates in patients with B-lineage ALL. Treatment outcomes in T-ALL patients remains poor due to high resistance to chemotherapy.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 375-383
Open AccessTreatment Outcomes in Children with Relapsed Acute Lymphoblastic Leukemia Using ALL-REZ BFM 2002 Protocol: Data from a Single-Center Trial
BACKGROUND. Despite considerable therapy success in newly diagnosed pediatric acute lymphoblastic leukemia (ALL), treatment of relapses remains challenging and requires a personalized approach. In the Russian Federation, the treatment of relapsed ALL is based on ALL-REZ BFM 2002, the protocol suggesting a risk-adapted strategy with assessing eligibility for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in high-risk patients. Global and national experience with implementation of this program demonstrated a therapeutic plateau, which indicates the need for modernizing the standard chemotherapy regimens and introducing novel targeted and immunological approaches. AIM. To assess the long-term outcomes of treating children with the first ALL relapse using ALL-REZ BFM 2002 at a single medical center. MATERIALS & METHODS. This study enrolled 73 patients with the confirmed diagnosis of the first ALL relapse who received a complete course of therapy according to ALL-REZ BFM 2002 at the Hematologic Malignancy Units No. 1 and No. 2 at the Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Cancer Research Center, from 2018 to 2024. The median age was 9.3 years (range 3–17 years), most of them were boys (71 %). The data analysis was conducted as of February 1, 2026. RESULTS. The analysis of the total cohort showed the 5-year overall survival of 54.6 % and event-free survival of 48.7 % (in the S1 and S2 risk subgroups 100 % and 52.2 %, respectively). Allo-HSCT improved the 5-year disease-free survival (DFS) up to 72.5 %. The administration of targeted immunotherapy with blinatumomab or inotuzumab ozogamicin as bridge therapy prior to allo-HSCT in minimal residual disease (MRD)-positive patients resulted in further improvement of this rate up to 83.6 %. CONCLUSION. The risk-adapted ALL-REZ BFM 2002 protocol shows efficacy in patients with the first ALL relapse. Introducing blinatumomab/inotuzumab ozogamicin to achieve MRD-negative remissions prior to allo-HSCT improves DFS rates in patients with B-lineage ALL. Treatment outcomes in T-ALL patients remains poor due to high resistance to chemotherapy.
- Open Access
- 8 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 44-51
Native and pegylated forms of L-asparaginase: the assessment of effectiveness and toxicity in acute lymphoblastic leukemia treated with Berlin–Frankfurt–Munster (BFM) protocol
Background. L-asparaginase is an integral part of chemotherapy regimens in treatment of patients with acute lymphoblastic leukemia (ALL). However, the use of L-asparaginase is limited due to wide range of adverse reactions. Our research demonstrates the toxicity effects and treatment results in patients with ALL who received native and pegylated (EG) L-asparaginase.Materials and methods. From 2013 to 2023 in the study 199 patients with newly diagnosed ALL were enrolled. Patients were treated according to the ALL IC-BFM 2009 protocol including L-asparaginase. The average age of patients was 4.6 (1–18) years. B-ALL was diagnosed in 175 (87.9 %) patients, T-ALL in 24 (12.1 %) patients. Native L-asparaginase was used in the therapy of 51 (25.6 %) patients; if allergic reactions occured, 72 (36.2 %) patients received EG asparaginase. In 76 (38.2 %) patients treatment protocol included only EG-asparaginase without native L-asparaginase history.Results. The most common adverse event was a hypersensitivity reaction – 27.6 % (n = 55), which was more common in the cohort of patients receiving native L-asparaginase. The incidence of hypercoagulation for patients treated with native L-asparaginase was 4 % and 0 % – for EG-asparaginase group. Hypocoagulation, presented as hypofibrinogenemia registered in 13 % of patients received native L-asparaginase and in 35 % for EG-asparaginase group. ancreatitis, complicated ALL treatment were diagnosed in 4 % after native L-asparaginase and 1 % after EG-asparaginase. The best 5‑year survival rates were observed in the group of patients who initially received EG-asparaginase – overall and eventfree survival were 100 and 87.5 (11.7) %, respectively (р 0.05).Conclusion. Despite the absence of convincing survival benefit in patients with newly diagnosed ALL treated with EG-asparaginase, the toxicity profile was better in contrast to native L-asparaginase.
- 8 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 44-51
Open AccessNative and pegylated forms of L-asparaginase: the assessment of effectiveness and toxicity in acute lymphoblastic leukemia treated with Berlin–Frankfurt–Munster (BFM) protocol
Background. L-asparaginase is an integral part of chemotherapy regimens in treatment of patients with acute lymphoblastic leukemia (ALL). However, the use of L-asparaginase is limited due to wide range of adverse reactions. Our research demonstrates the toxicity effects and treatment results in patients with ALL who received native and pegylated (EG) L-asparaginase.Materials and methods. From 2013 to 2023 in the study 199 patients with newly diagnosed ALL were enrolled. Patients were treated according to the ALL IC-BFM 2009 protocol including L-asparaginase. The average age of patients was 4.6 (1–18) years. B-ALL was diagnosed in 175 (87.9 %) patients, T-ALL in 24 (12.1 %) patients. Native L-asparaginase was used in the therapy of 51 (25.6 %) patients; if allergic reactions occured, 72 (36.2 %) patients received EG asparaginase. In 76 (38.2 %) patients treatment protocol included only EG-asparaginase without native L-asparaginase history.Results. The most common adverse event was a hypersensitivity reaction – 27.6 % (n = 55), which was more common in the cohort of patients receiving native L-asparaginase. The incidence of hypercoagulation for patients treated with native L-asparaginase was 4 % and 0 % – for EG-asparaginase group. Hypocoagulation, presented as hypofibrinogenemia registered in 13 % of patients received native L-asparaginase and in 35 % for EG-asparaginase group. ancreatitis, complicated ALL treatment were diagnosed in 4 % after native L-asparaginase and 1 % after EG-asparaginase. The best 5‑year survival rates were observed in the group of patients who initially received EG-asparaginase – overall and eventfree survival were 100 and 87.5 (11.7) %, respectively (р 0.05).Conclusion. Despite the absence of convincing survival benefit in patients with newly diagnosed ALL treated with EG-asparaginase, the toxicity profile was better in contrast to native L-asparaginase.
- Open Access
- 6 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 23-31
The role of high-dose methotrexate in T-cell acute lymphoblastic leukemia treatment: multicenter study results of ALL IC-BFM 2002 protocol
Backround. A progress in Tcell acute lymphoblastic leukemia (TALL) treatment has been achieved in recent years by use a combination of riskadopted chemoradiation therapy, based on highdose (5000 mg/m2) methotrexate. A prerequisite for successful therapy is carefully follow supportive care principles and recommendations, which include blood serum methotrexate concentration monitoring, leucovorin rescue and alkaline solutions use for the best methotrexate elimination and decrease its toxic effects.Aim. To assess the effectiveness of ALL ICFM 2002 protocol based on highdose methotrexate for Tcell acute lymphoblastic leukemia.Materials and methods. From 2003 to 2023 in retroprospective study 67 patients with primary diagnosed TALL were enrolled. Median age was 7.4 years (from 0 to 18 years). All the patients were treated according to riskadopted ALL ICFM 2002 protocol. The therapy efficacy was assessed by overall (OS), eventfree (EFS) and relapsefree survival analysis. The survival rates were calculated with statistic program SSS 21.0 by Kaplan–Meier method.Results. The use of highdose methotrexate for TALL treatment in ALL ICFM 2002 protocol secure high survival rates: 10‑year OS was 82.5 ± 3 %, EFS – 79.3 ± 3 %. Analyzing OS and EFS depending on prognostic risk group we found that standard risk patients had OS and EFS 85.4 ± 6.9 and 78.4 ± 8 %, intermediate – 85.6 ± 6.7 and 82 ± 7.3 % and highrisk – 34.6 ± 18.3 and 20.8 ± 17.1 % respectively (р 0.05).Conclusion. ALL ICFM 2002 protocol for TALL includes highdose (5000 mg/m2) methotrexate is an effective for standard and intermediate risk patients, but for TALL patients with unfavorable prognostic factors it is necessary a therapy modification by additional cytotoxic and targeted options (nelarabine and daratumumab) inclusion and widening the indications for allogeneic stem cell transplantation.
- 6 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 23-31
Open AccessThe role of high-dose methotrexate in T-cell acute lymphoblastic leukemia treatment: multicenter study results of ALL IC-BFM 2002 protocol
Backround. A progress in Tcell acute lymphoblastic leukemia (TALL) treatment has been achieved in recent years by use a combination of riskadopted chemoradiation therapy, based on highdose (5000 mg/m2) methotrexate. A prerequisite for successful therapy is carefully follow supportive care principles and recommendations, which include blood serum methotrexate concentration monitoring, leucovorin rescue and alkaline solutions use for the best methotrexate elimination and decrease its toxic effects.Aim. To assess the effectiveness of ALL ICFM 2002 protocol based on highdose methotrexate for Tcell acute lymphoblastic leukemia.Materials and methods. From 2003 to 2023 in retroprospective study 67 patients with primary diagnosed TALL were enrolled. Median age was 7.4 years (from 0 to 18 years). All the patients were treated according to riskadopted ALL ICFM 2002 protocol. The therapy efficacy was assessed by overall (OS), eventfree (EFS) and relapsefree survival analysis. The survival rates were calculated with statistic program SSS 21.0 by Kaplan–Meier method.Results. The use of highdose methotrexate for TALL treatment in ALL ICFM 2002 protocol secure high survival rates: 10‑year OS was 82.5 ± 3 %, EFS – 79.3 ± 3 %. Analyzing OS and EFS depending on prognostic risk group we found that standard risk patients had OS and EFS 85.4 ± 6.9 and 78.4 ± 8 %, intermediate – 85.6 ± 6.7 and 82 ± 7.3 % and highrisk – 34.6 ± 18.3 and 20.8 ± 17.1 % respectively (р 0.05).Conclusion. ALL ICFM 2002 protocol for TALL includes highdose (5000 mg/m2) methotrexate is an effective for standard and intermediate risk patients, but for TALL patients with unfavorable prognostic factors it is necessary a therapy modification by additional cytotoxic and targeted options (nelarabine and daratumumab) inclusion and widening the indications for allogeneic stem cell transplantation.
- 28 May 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (3)
CONSEQUENCES OF LATE DIAGNOSIS OF LYMPHOMAS IN CHILDREN
Lymphoma is the third leading cause of malignant neoplasms (MNs) in children. Childhood lymphoma is characterized by the prevalence of highly aggressive variants with high proliferation activity and rapid tumor dissimilation. Prolonged diagnosis becomes a reason of advanced-stage therapy. Despite the good results of long-term survival rate in patients, exceeding 90% even with late (III-IV) stages of lymphomas, the persistence of pathogenic (including multi-drug resistant) microorganisms in the patient's body becomes a major therapeutic problem, contamination of which occurs during the patient's stay in various medical organizations at the stage of diagnostics. The case reports of fatal infectious complications with the development of sepsis caused by polyresistant microorganisms in 2 children with anaplastic large cell lymphoma stage IV are presented in this article. Both case reports are unfavourable, despite the use of all medications and effective treatments. The analysis of diagnostic errors and necessity of cancer alarm generation in medical staff and patients' parents will make it possible to reduce the duration of diagnosis and probability of contamination of patient’s body with multi-resistant flora.
- 28 May 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (3)
CONSEQUENCES OF LATE DIAGNOSIS OF LYMPHOMAS IN CHILDREN
Lymphoma is the third leading cause of malignant neoplasms (MNs) in children. Childhood lymphoma is characterized by the prevalence of highly aggressive variants with high proliferation activity and rapid tumor dissimilation. Prolonged diagnosis becomes a reason of advanced-stage therapy. Despite the good results of long-term survival rate in patients, exceeding 90% even with late (III-IV) stages of lymphomas, the persistence of pathogenic (including multi-drug resistant) microorganisms in the patient's body becomes a major therapeutic problem, contamination of which occurs during the patient's stay in various medical organizations at the stage of diagnostics. The case reports of fatal infectious complications with the development of sepsis caused by polyresistant microorganisms in 2 children with anaplastic large cell lymphoma stage IV are presented in this article. Both case reports are unfavourable, despite the use of all medications and effective treatments. The analysis of diagnostic errors and necessity of cancer alarm generation in medical staff and patients' parents will make it possible to reduce the duration of diagnosis and probability of contamination of patient’s body with multi-resistant flora.
- Open Access
- 31 December 2019
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 21 (4) , 22-26
Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy. Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival. Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol. MRD levels were determined by flow cytometry. Results. Given the MRD based stratification, a truly standard risk group was identified, the survival rate of which reached 100%. Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future.
- 31 December 2019
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 21 (4) , 22-26
Open AccessModern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy. Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival. Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol. MRD levels were determined by flow cytometry. Results. Given the MRD based stratification, a truly standard risk group was identified, the survival rate of which reached 100%. Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future.